Athira Pharma (ATHA) Expected to Announce Earnings on Wednesday

Athira Pharma (NASDAQ:ATHA) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect Athira Pharma to post earnings of ($0.20) per share for the quarter.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). On average, analysts expect Athira Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Athira Pharma Price Performance

Athira Pharma stock opened at $0.27 on Tuesday. The firm has a market capitalization of $10.62 million, a price-to-earnings ratio of -0.10 and a beta of 3.04. The company’s 50 day simple moving average is $0.28 and its 200 day simple moving average is $0.45. Athira Pharma has a fifty-two week low of $0.22 and a fifty-two week high of $3.67.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.